98%
921
2 minutes
20
Introduction: The incidence and mortality rate from depression are increasing year by year, and depression has become the main cause of global health loss and disability. Currently, the treatment of depression mainly relies on drug intervention. However, the vast majority of antidepressants exhibit significant pharmacological variability, resulting in individual differences in steady-state blood drug concentrations even with the same dosing regimen among patients. Therefore, using therapeutic drug monitoring (TDM) to guide the precise use of antidepressants has important clinical significance.
Methods: In this paper, we developed a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method to study simultaneously TDM and clinical pharmacokinetics of 23 antidepressants and active metabolites: sertraline, escitalopram, fluvoxamine, paroxetine, duloxetine, milnacipran, fluoxetine, venlafaxine, O-desmethylvenlafaxine, mirtazapine, trazodone, bupropion, hydroxybupropione, norfluoxetine, vortioxetine, agomelatine, mianserin, doxepine, desmethyldoxepin, clomipramine, desmethylclomipramine, amitriptyline and nortriptyline hydrochloride. After protein precipitation of serum samples with acetonitrile, the isotope internal standards (ISs), antidepressants and active metabolites were separated using a ZORBAX Eclipse Plus C18 column (50.0 mm × 2.1 mm, 1.7 µm) with water containing 0.1% formic acid and 10 mmol/L ammonium acetate and methanol containing 0.1% formic acid. Validation of the developed method was carried out based on the Chinese Pharmacopoeia guidelines for bioanalytical method validation, including assessment of specificity, calibration curves, carryover, accuracy, crosstalk, precision, stability, recovery, dilution integrity and matrix effect.
Results: The results showed that a simple, fast, reliable and specific HPLC'MS/MS method was developed and validated, and all the performance characteristics of the method met the requirements, which could be used to study TDM and pharmacokinetics of the above 23 antidepressants and active metabolites.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983492 | PMC |
http://dx.doi.org/10.3389/fphar.2025.1531496 | DOI Listing |
Proc Natl Acad Sci U S A
September 2025
Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN 37240.
Major depressive disorder affects millions worldwide, yet current treatments require prolonged administration. In contrast, ketamine produces rapid antidepressant effects by blocking spontaneous N-Methyl-D-Aspartate (NMDA) receptor signaling, which lifts the suppression of protein synthesis and triggers homeostatic synaptic plasticity. Here, we identify a parallel signaling pathway involving metabotropic glutamate receptor 5 (mGluR5) that promotes rapid antidepressant-like effects.
View Article and Find Full Text PDFMetab Brain Dis
September 2025
Department of Pharmacology, SVKM's Dr Bhanuben Nanavati College of Pharmacy, V.M. Road, Vile Parle (W), Mumbai, India.
This study aimed to evaluate the antidepressant potential of Nitazoxanide (NTZ), an antiprotozoal drug with known anti-inflammatory and neuroprotective properties, in a chronic unpredictable mild stress (CUMS)-induced mice model of depression. NTZ was administered at doses of 75, 150, and 300 mg/kg, and its effects were assessed through a series of behavioral tests, including the forced swim test, tail suspension test, actophotometer test, and social interaction test. NTZ treatment at 150 and 300 mg/kg significantly improved behavioral and biochemical outcomes, relieving depressive-like symptoms and restoring neurochemical balance.
View Article and Find Full Text PDFJAACAP Open
September 2025
H. Lundbeck A/S, Copenhagen, Denmark.
Objective: To evaluate efficacy, safety, and tolerability of vortioxetine in children ages 7 to 11 years with major depressive disorder.
Method: Patients meeting criteria for incomplete improvement in depressive symptoms (Children's Depression Rating Scale-Revised [CDRS-R] total score ≥40 plus <40% reduction and Parent Global Assessment Global Improvement score >2) after 4 weeks of single-blind lead-in treatment with a brief psychosocial intervention plus placebo were randomized 1:1:1:1 to 8-week double-blind treatment with brief psychosocial intervention and placebo, vortioxetine 10 mg/day, vortioxetine 20 mg/day, or fluoxetine 20 mg/day. Following preplanned interim analysis, enrollment to fluoxetine was stopped, and patients were randomized 1:1:1 to placebo, vortioxetine 10 mg, or vortioxetine 20 mg.
Drug Dev Res
September 2025
Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, P. R. China.
The structural modification and derivatization of natural products represent an essential pathway for pharmaceutical innovation in the management of depression. The 8-phenyl tetrahydroisoquinoline, as a parent core, was obtained from magnoflorine by a structural simplification strategy. The present report details the synthesis and antidepressant activity studies of 8-phenyl-THIQ analogs.
View Article and Find Full Text PDFJ Affect Disord
September 2025
CORE Data Lab, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK; Research Department of Clinical, Educational and Health Psychology, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK; iCope, Camden and Islington NHS Talking Therapies for anxiety and depress
Background: Anhedonia, the lack of interest or pleasure in activities, is a core but under-addressed symptom of depression. Consequently, little is known about the efficacy of treatments for alleviating anhedonia.
Objective: To evaluate the efficacy of psychotherapeutic and pharmacological treatments for depression at reducing symptoms of anhedonia.